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While Brazil is second only to the United States in terms of
the absolute number of kidney and liver transplants, the
number of lung transplantations remains modest. According
to the Brazilian Registry of Transplantation, in 2019 only 106
lung transplants were performed across seven institutions.
Three hospitals were responsible for 83% of these procedures,
of which the Instituto do Coração (InCor) of HCFMUSP
was responsible for 42% of these transplants. The reason for
having only a few centers trained to perform lung transplan-
tation lies in the complexity of the organ which is one of the
most immunogenic organs. With only a few centers, patients
with advanced lung disease have difficulty in seeking care. As
of December 2019, 187 patients were on the waiting list for
lung transplant, and over the course of the year, 39 patients
died while still on the waiting list, which denotes a mortality
rate of 21.2%. This demonstrates the severity of the situation;
the demand for transplants is greater than the availability of
organs. We wished to examine the expected effect of the new
coronavirus disease 2019 (COVID-19) pandemic on lung
transplantation.
COVID-19 is a disease caused by the severe acute respi-
ratory syndrome coronavirus 2 virus (SARS-CoV-2) first
reported in December 2019 in the city of Wuhan, China, and
has spread rapidly around the world. Since the lung is the
principal organ affected by COVID-19, the first concern for
transplantation during this pandemic is to establish safe
organ donation. How do we establish safety? Initial recom-
mendations were based on the likelihood of donor infection
and their exposure to known or probable cases within 14
days prior to donation. In that scenario, reverse transcription
polymerase chain reaction (RT-PCR) tests for SARS-CoV-2
were desirable but not mandatory, along with chest computed
tomography to assess pulmonary infiltrates suspicious of viral
injury (1). However, as community transmission became more
prevalent, ANVISA (Agência Nacional de Vigilância Sanitá-
ria - National Agency of Health Surveillance) established
the need for RT-PCR tests for SARS-CoV-2 for all cadaveric
donors. Based on discussions with experts around the world,
we have decided to accept donors in the following situations:
(1) SARS-CoV-2 negative RT-PCR within 24 hours before
transplantation, (2) no history of COVID-19 or previous
suspicion, (3) preferably with chest tomography showing
no pulmonary infiltrates suggestive of acute injury in less
than 24 hours before transplantation. With regards to the reci-
pient, the nasal swab is collected however, as there is no time
to wait for the results of the RT-PCR, we proceed with the
transplant in recipients without symptoms, and with a nega-
tive chest tomography with no signs of recent pulmonary
infiltrates.
The effect of the pandemic on the demand for multiple
organ donors in the State of São Paulo was evident. By way
of comparison, the transplant group at InCor receives an
average of 60 notifications per month. In April 2020, there
were 41 notifications, resulting in only two transplants per
month: one patient prioritized in extracorporeal membrane
oxygenation (ECMO) and another type AB recipient.
Ethical considerations of performing transplantation dur-
ing this pandemic must also be examined, because despite
all the recommended care previously mentioned, the risk
of COVID-19 in transplant patients remains uncertain. In a
report by Pereira et al., of the 90 patients with solid organ
transplantation in New York City who tested positive for
SARS-CoV2, 68 required hospitalization and 16 patients
(18%) died of the disease. Among the 90 transplant patients,
17 received lung transplants of whom 41% had severe mani-
festations of the disease. There is no information on the mor-
tality in this subgroup (2). In contrast, Aigner et al., based
on his own experience of a single transplant recovered after
infection suggests the satisfactory evolution of immunosup-
pressed patients infected with COVID-19 (3).
Without being able to predict the effect of COVID-19 in
immunosuppressed patients, defining the ideal recipient in
this situation is complex. The capabilities of the hospital and
its intensive care beds must also be considered. Assuming
there is transmission control and adequate human and material
resources, the transplant community believes that the program
should be conducted normally. However, patients who are
stable, with no progression of the disease and, and can wait
for three to six months, must be educated on the risks of
transplantation during this pandemic. In a webinar pro-
moted by the International Society for Heart and Lung Trans-
plantation (ISHLT) with specialists from different countries,
the need to perform transplantation in patients at a greater
risk of respiratory decline, such as patients with rapidly evol-
ving pulmonary fibrosis or pulmonary hypertension, was
clear. If the in-hospital scenario worsens, for example,
increase in-hospital transmission and depletion of resources,
transplants can be restricted only to those patients in emergentDOI: 10.6061/clinics/2020/e1978
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need who have a risk of imminent death (priority) and who are
on mechanical ventilation or under care (ECMO).
The safety of the transplant team and the professionals
involved must also be a priority at this stage. Despite the
results of the RT-PCR for SARS-CoV-2 in both donors and
recipients, the use of suitable personal protective equipment
(PPE) in the organ procurement and implantation process is
essential, since airway manipulation during lung transplan-
tation is continuous.
What has been observed in Europe is a global reduction in
the number of lung transplants, both due to the decrease
in the number of donors, and the exhaustion of the health
system. There is still no information on the impact of
COVID-19 on lung transplantation in the United States.
However, there are several transplant Centers in US and once
the spread of the pandemic has not been uniform, some
centers are still maintaining their transplant programs close
to normal. The outlook that is expected in Brazil should
be similar to what has been occurring in Europe, but further
impacted by the fact that few centers account for almost all
lung transplant procedures. Any effect on one of these centers
will have a very large impact on this modality and from what
has been observed so far, there will certainly be fewer donors,
and fewer transplants in the coming months.
As this crisis is undoubtedly going to expose the level of
preparedness of the health care system in Brazil, the need to
encourage more lung transplant centers is evident, so that
patients in need are not obliged to travel away from their
home cities in search of such an exclusive modality. Given
that the lung transplantation programs are poorly funded,
both by the Unified Health System (SUS) and by insurance
companies, only seven teams are registered in Brazil to
perform this procedure. It is worth mentioning that although
Brazil has the largest public transplant program in the world
which started in 1989, the National Supplementary Health
Agency (ANSS) does not yet recognize this modality within
the list of procedures to be covered by health operators. For
comparison, this activity is well funded by the Insurance
Companies in US where there are 69 active programs
registered with UNOS (2,652 transplants performed in
2018) and 174 programs registered on the ISHLT platform,
responsible for 4452 lung transplants performed around the
world annually.
Thus, at a time when COVID-19 cases are increasing on
a logarithmic scale with more than 90,000 cases and 6,329
deaths in Brazil (30,374 cases and 2,511 deaths in the State
of São Paulo)1, it is expected that the number of lung
transplantations will significantly increase.
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